Published in Antimicrob Agents Chemother on September 23, 2016
The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Front Pharmacol (2017) 0.75
The Etest performed directly on blood culture bottles is a reliable tool for detection of fluconazole-resistant Candida albicans isolates. Antimicrob Agents Chemother (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene (1987) 25.43
Genealogy of principal strains of the yeast genetic stock center. Genetics (1986) 6.00
Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother (1997) 5.66
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med (2004) 4.30
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother (1996) 4.24
Vulvovaginal candidosis. Lancet (2007) 3.50
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
Usefulness of multilocus sequence typing for characterization of clinical isolates of Candida albicans. J Clin Microbiol (2002) 3.01
Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun (2003) 2.67
The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother (1999) 2.26
Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol (2000) 1.77
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother (2001) 1.54
Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems. J Clin Microbiol (1999) 1.54
Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother (1999) 1.54
Infection-related gene expression in Candida albicans. Curr Opin Microbiol (2007) 1.50
Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res (2009) 1.48
Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun (2000) 1.44
Candida albicans drug resistance another way to cope with stress. Microbiology (2007) 1.35
Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell (2007) 1.35
The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob Agents Chemother (2004) 1.33
Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology (2008) 1.28
Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (2015) 1.23
Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother (2003) 1.22
Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell (2012) 1.16
Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. Front Microbiol (2012) 1.14
The evolution of drug resistance in clinical isolates of Candida albicans. Elife (2015) 1.10
A fourth gene from the Candida albicans CDR family of ABC transporters. Gene (1998) 1.09
Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Anal Biochem (2009) 1.08
Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol (2012) 1.04
Microbial growth patterns in a total parenteral nutrition formulation containing lipid emulsion. JPEN J Parenter Enteral Nutr (1986) 1.01
Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother (2011) 1.01
Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother (2012) 0.90
Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development. Curr Med Chem (1999) 0.90
A key structural domain of the Candida albicans Mdr1 protein. Biochem J (2012) 0.88
Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity. Antimicrob Agents Chemother (2013) 0.87
Comparison of the Sensititre YeastOne® dilution method with the Clinical Laboratory Standards Institute (CLSI) M27-A3 microbroth dilution reference method for determining MIC of eight antifungal agents on 102 yeast strains. Pathol Biol (Paris) (2010) 0.84
A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol (2002) 0.84
Amplification of the hyphal wall protein 1 gene to distinguish Candida albicans from Candida dubliniensis. J Clin Microbiol (2006) 0.84
Management of patients with recurrent vulvovaginal candidiasis. Drugs (2003) 0.83
Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance. Infect Dis Clin North Am (2015) 0.77
Rapid differentiation of Candida dubliniensis from Candida albicans by early D-xylose assimilation. Med Princ Pract (2012) 0.76